Arvinas (NASDAQ:ARVN) Hits New 52-Week Low - What You Need to Know

Arvinas, Inc. (NASDAQ:ARVN) experienced a significant drop in its stock price, reaching a new 52-week low during trading on Thursday. The shares fell to a low of $7.83 before closing at $7.85, with a total of 677,217 shares traded. This decline follows a previous close of $7.95.

Analyst Opinions and Forecasts

Recent analyst reports have addressed Arvinas's performance. Guggenheim adjusted their target price from $57.00 to $32.00 while maintaining a "buy" rating. Meanwhile, Barclays cut their price target from $48.00 to $32.00 and designated the stock as "overweight." Oppenheimer changed their rating from "outperform" to "market perform." Bank of America also reduced its price target from $54.00 to $28.00, keeping a "buy" rating. Additionally, BMO Capital Markets set a target price of $20.00 and gave it an "outperform" rating. Overall, five analysts have rated the stock as a hold, while ten have issued buy ratings, leading to a consensus average rating of "Moderate Buy" and a price target of $35.50 according to MarketBeat data.

Arvinas' Price and Financial Metrics

The company has a 50-day moving average of $15.67 and a 200-day moving average of $20.91. With a market cap of approximately $549.49 million, Arvinas shows a negative P/E ratio of -2.87 and a beta of 1.95. In its latest earnings report from February 11, the company reported an earnings per share (EPS) of ($0.63), surpassing analyst expectations of ($1.07) by $0.44. The firm had a negative net margin of 75.51% and a negative return on equity of 33.75%. For the current fiscal year, analysts predict EPS will be -3.81.

Insider Transactions

In recent insider trading news, Ian Taylor, a company insider, sold 9,020 shares on February 24, receiving about $150,724 from the sale. Following this transaction, he owns approximately 159,121 shares valued at around $2.66 million. CEO John G. Houston also sold 31,338 shares on the same day for roughly $524,000, reducing his ownership to 1,157,480 shares worth about $19.35 million. In the last quarter, insiders sold a total of 50,230 shares valued at approximately $769,402, accounting for 5.23% of the stock still held by insiders.

Institutional Holdings

Institutional investors have recently shifted their positions in Arvinas. GF Fund Management bought a new stake worth around $28,000 during the fourth quarter. KBC Group NV raised its shares by 77% in this same period, now holding 2,885 shares valued at $55,000. Quantbot Technologies increased its holdings by 147.3% during the third quarter, now owning 4,367 shares worth $108,000. KLP Kapitalforvaltning AS and Tema Etfs LLC also acquired new stakes valued at $171,000 and $227,000, respectively. Overall, institutional investors and hedge funds own approximately 95.19% of Arvinas' shares.

Company Overview

Arvinas, Inc. operates as a clinical-stage biotechnology firm focused on discovering and developing therapies that target and degrade disease-causing proteins. The company employs proteolysis targeting chimeras (PROTAC) technology to utilize the body’s natural protein disposal mechanisms.

Additional Insights

Investors considering Arvinas should weigh market opinions and recent performance metrics. While analysts currently rate the stock as a "Moderate Buy," higher-rated analysts suggest looking for alternative investment opportunities.

stocks, analysis, trading